These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4844125)

  • 1. Half life of intravenous tolbutamide in the serum of patients in medical wards.
    Sotaniemi EA; Huhti E
    Ann Clin Res; 1974 Jun; 6(3):146-54. PubMed ID: 4844125
    [No Abstract]   [Full Text] [Related]  

  • 2. [Early diagnosis of diabetes mellitus. Results of the intravenous tolbutamide test in 1048 patients].
    Trautwein H; Julitz R
    Med Klin; 1969 Dec; 64(51):2376-81. PubMed ID: 5381207
    [No Abstract]   [Full Text] [Related]  

  • 3. [Serum urocaninase in circulatory insufficiency].
    Nedogoda VV; Muzhichenko AV
    Ter Arkh; 1972 Jun; 44(6):61-5. PubMed ID: 4148735
    [No Abstract]   [Full Text] [Related]  

  • 4. Half-life of tolbutamide in patients with chronic respiratory failure.
    Sotaniemi E; Arvela P; Huhti E; Koivisto O
    Eur J Clin Pharmacol; 1971 Dec; 4(1):29-31. PubMed ID: 5151390
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of pargyline with tolbutamide in rabbits.
    Satyanarayana S; Krishna DM; Krishnaiah YS; Visweswaram D
    Indian J Physiol Pharmacol; 1995 Jan; 39(1):71-3. PubMed ID: 7705875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific determinations of prothrombin for evaluation of liver function.
    Norén I; Blombäck M
    Acta Med Scand; 1972 Mar; 191(3):257-62. PubMed ID: 5033717
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.
    Andreasen PB; Vesell ES
    Clin Pharmacol Ther; 1974 Dec; 16(6):1059-65. PubMed ID: 4611464
    [No Abstract]   [Full Text] [Related]  

  • 8. [Influence of allopurinol on the half-life of tolbutamide and rifamycin-SV in blood of healthy volunteers].
    Gentile S; Porcellini M; Foglia F; Loguercio C; Coltorti M
    Boll Soc Ital Biol Sper; 1979 Feb; 55(4):345-8. PubMed ID: 552849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of alcohol and tolbutamide blood clearance rates with microsomal alcohol-metabolizing enzyme activity.
    Kostelnik ME; Iber FL
    Am J Clin Nutr; 1973 Feb; 26(2):161-4. PubMed ID: 4145020
    [No Abstract]   [Full Text] [Related]  

  • 10. [Evaluation of the intravenous tolbutamide test in hepatic damage].
    Enrique Forteza M; Miretti J
    Prensa Med Argent; 1971 Nov; 58(36):1796-800. PubMed ID: 5160062
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug interaction during therapy with tolbutamide. The influence of some commonly used drugs on plasma level and half life in diabetic out-patients (author's transl)].
    Kolenda KD; Grille W; Johnsen K
    Med Klin; 1979 Dec; 74(50):1914-22. PubMed ID: 542176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Furosemide--pharmacokinetics in geriatric patients with multimorbidity].
    Neubig E; Mühlberg W; Platt D
    Z Gerontol; 1984; 17(5):251-60. PubMed ID: 6523981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
    Gachályi B; Tornyossy M; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases.
    Held H; Eisert R; von Oldershausen HF
    Arzneimittelforschung; 1973 Dec; 23(12):1801-7. PubMed ID: 4801689
    [No Abstract]   [Full Text] [Related]  

  • 15. [The intravenous tolbutamide test].
    Rambert P; Thervet F
    Journ Annu Diabetol Hotel Dieu; 1968; 9():331-45. PubMed ID: 4918340
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma fibrin stabilising factor (F.S.F.) activity in normal subjects and patients with chronic liver disease.
    Walls WD; Losowsky MS
    Thromb Diath Haemorrh; 1969 Feb; 21(1):134-43. PubMed ID: 5773724
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravenous dehydrocholate tolerance test in patients with liver disease.
    Wakushima T; Kishimoto Y; Hirayama C
    Hepatogastroenterology; 1983 Aug; 30(4):137-9. PubMed ID: 6629304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of phenylbutazone and tolbutamide in man.
    Szita M; Gachályi B; Tornyossy M; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):378-80. PubMed ID: 7450929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term tolbutamide effect on patients with liver cirrhosis.
    Hirayama C; Kawasaki H; Arimura K; Amagase H
    Acta Hepatogastroenterol (Stuttg); 1974 Feb; 21(1):34-40. PubMed ID: 4450960
    [No Abstract]   [Full Text] [Related]  

  • 20. Kanamycin serum half-life and renal function: age and sex.
    Nielsen B; Sorensen AW; Szabo L; Pedersen EA; Scharff A
    Dan Med Bull; 1973 Oct; 20(5):144-9. PubMed ID: 4770767
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.